Mucinous cystadenocarcinoma natural history

Mucinous cystadenocarcinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Mucinous Cystadenocarcinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Mucinous cystadenocarcinoma natural history On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Mucinous cystadenocarcinoma natural history All Images X-rays Echo and Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Mucinous cystadenocarcinoma natural history
CDC on Mucinous cystadenocarcinoma natural history
Mucinous cystadenocarcinoma natural history in the news
Blogs on Mucinous cystadenocarcinoma natural history
Directions to Hospitals Treating Mucinous cystadenocarcinoma
Risk calculators and risk factors for Mucinous cystadenocarcinoma natural history

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Natural History

• Most of the mucinous cytoadenocarcinoma of ovary is confined to ovary and advanced stages of the carcinoma can have metastasis to the gastrointestinal tract.

Complications

• Metastasis

Prognosis

• Advanced stages of mucinous cystadenocarcinoma have inferior prognosis.
• MCACL has a much more favorable prognosis than most other forms of adenocarcinoma and most other NSCLC's.[9][14] Cases have been documented of continued growth of these lesions over a period of 10 years without symptoms or metastasis. The overall mortality rate appears to be somewhere in the vicinity of 18% to 27%, depending on the criteria that are used to define this entity.